XANTHINOL NIACINATE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H21N5O4.C6H5NO2
Molecular Weight	434.4463
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=CC=CN=C1.CN(CCO)CC(O)CN2C=NC3=C2C(=O)N(C)C(=O)N3C

InChI

InChIKey=GEPMAHVDJHFBJI-UHFFFAOYSA-N

InChI=1S/C13H21N5O4.C6H5NO2/c1-15(4-5-19)6-9(20)7-18-8-14-11-10(18)12(21)17(3)13(22)16(11)2;8-6(9)5-2-1-3-7-4-5/h8-9,19-20H,4-7H2,1-3H3;1-4H,(H,8,9)

HIDE SMILES / InChI

Molecular Formula	C6H5NO2
Molecular Weight	123.1094
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C13H21N5O4
Molecular Weight	311.3369
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/772653 | https://www.medicineindia.org/pharmacology-for-generic/759/xanthinol-nicotinate | https://www.ncbi.nlm.nih.gov/pubmed/8378412 | https://www.ncbi.nlm.nih.gov/pubmed/540521 | https://www.drugbank.ca/drugs/DB09092

Xanthinol (xanthinol nicotinate) is a xanthine derivative, peripheral vasodilator agent. It exerts it`s pharmacological action by acting as a vasodilator and improves blood flow to brain, arteries, and to the periphery. It increases brain glucose metabolism and thus improves brain ATP levels. It stimulates memory and concentration elevates brain energy levels. Indications for Xanthinol Nicotinate: 1. Peripheral vascular sclerosis 2. Cerebral circulatory disorders 3. Arteriosclerosis 4. Endarteritis obliterans 5. Short term memory disorders 6. Mental flagging 7. Anti ageing memory support 8. Diabetic angiopathy 9. Diabetic gangrene 10. Hyperlipidaemia 11. Intermittent claudication Side Effects of Xanthinol Nicotinate: 1. Flushing 2. Feeling of warmth 3. Nausea 4. Heart burn 5. Vomiting 6. Itching of skin For 30 years, Xanthinol nicotinate has been on the market for the treatment of impaired brain function, i.e., organic brain syndromes of various etiologies. Controlled double-blind phase-III clinical trials have shown that xantinol nicotinate is also an effective drug in the treatment of dementia. Xanthinol nicotinate is also helpful in the management of leg ulcers associated with haemoglobinopathies. Xanthinol was approved as a drug in 1998 in Canada and nowadays its status is cancelled post marketing. The positively charged xanthinol ion is thought to help the transportation of the nicotinic acid into the cell since the later cannot freely diffuse through the cell membrane. The mechanism of action is thought to be related to present influence in the cell metabolism through the nucleotides NAD and NADP. Also, the nicotinic acid is a coenzyme for a lot of proteins involved in tissue respiration (Embden-Meyerhof and citrate cycle). The effect of xanthinol nicotinate causes an increase in glucose metabolism and energy gain.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Peripheral vascular disease 2 Sources: https://www.tabletwise.com/medicine/xanthinol-nicotinate/uses-benefits-working https://www.medicineindia.org/pharmacology-for-generic/759/xanthinol-nicotinate https://www.ndrugs.com/?s=complamin	Primary		Approved 8583	Complamin Approved Use Xanthinol Nicotinate (Complamin) is a vasodilator used for the treatment of Peripheral vascular disease, Cerebrovascular disorders and other conditions.
Cerebrovascular disorders 2 Sources: https://www.tabletwise.com/medicine/xanthinol-nicotinate/uses-benefits-working https://www.medicineindia.org/pharmacology-for-generic/759/xanthinol-nicotinate https://www.ndrugs.com/?s=complamin	Primary		Approved 8583	Complamin Approved Use Xanthinol Nicotinate (Complamin) is a vasodilator used for the treatment of Peripheral vascular disease, Cerebrovascular disorders and other conditions. Launch Date 1992

C_max

Value	Dose	Co-administered	Analyte	Population
615 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18718822/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		XANTHINOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
4457 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18718822/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		XANTHINOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
4.89 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18718822/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		XANTHINOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
141.7 mg 3 times / day steady, respiratory Studied dose Dose: 141.7 mg, 3 times / day Route: respiratory Route: steady Dose: 141.7 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3936095/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3936095/	Sources: https://pubmed.ncbi.nlm.nih.gov/3936095/
600 mg 3 times / day multiple, oral Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7358205/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7358205/	Sources: https://pubmed.ncbi.nlm.nih.gov/7358205/
600 mg 4 times / day steady, oral Studied dose Dose: 600 mg, 4 times / day Route: oral Route: steady Dose: 600 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/540521/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/540521/	Disc. AE: Itching... AEs leading to discontinuation/dose reduction: Itching (severe, 3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/540521/

AEs

AE	Significance	Dose	Population
Itching	severe, 3 patients Disc. AE	600 mg 4 times / day steady, oral Studied dose Dose: 600 mg, 4 times / day Route: oral Route: steady Dose: 600 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/540521/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/540521/

PubMed

Title	Date	PubMed
[Peyronie's disease: comparative results of conservative treatment].	2011-03-25	21427993
Use of Xanthinol Nicotinate as a co-treatment for radio- and chemo-therapy in experimental tumors.	2010-01-15	19585554
Novel inhibitors of HIV discovered among existing classes of pharmaceutical compounds indicated for unrelated clinical indications.	2009	19355959
Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of xanthinol in human plasma and its application in a bioequivalence study of xanthinol nicotinate tablets.	2008-09-15	18718822
[Sudden hearing loss--our experience in treatment with vasoactive therapy].	2008-08-30	18720739
[Pathogenetic basis for using prodectin and teonicol, redergin and aescuzan in complex treatment of chronic gastritis].	2002	12353381
Psoriasis and side-effects of mesotherapy.	2001-09	11737454

Sample Use Guides

In Vivo Use Guide

Typical Dosage for Xanthinol Nicotinate Oral: 300mg 8th hourly. Increases the dosage up to 600mg 8th hourly if required. Maximum dose: 1800mg/day. I.V. or I.M.: 300mg. Maximum dose: 900mg.

Route of Administration: Other

In Vitro Use Guide

HUASMCs were treated with different concentrations of Xanthinol (xanthinol nicotinate) (0, 2.76, 27.6 or 276 uM), and a 3-(4,5-dimethylthiazol-2yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was used to detect the inhibition of HUASMC proliferation.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:29:44 GMT 2025` Edited by `admin` on `Mon Mar 31 19:29:44 GMT 2025`
Record UNII	8G60H12X2D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

XANTHINOL NIACINATE

Official Name

English

XANTINOL NICOTINATE

Preferred Name

English

xantinol nicotinate [INN]

Common Name

English

XANTHINOL NIACINATE [MI]

Common Name

English

COMPLAMIN

Brand Name

English

XANTHINOL NIACINATE [USAN]

Common Name

English

7-{2-Hydroxy-3-[(2-hydroxyethyl)methylamino]propyl}theophylline, compound with nicotinic acid (1:1)

Systematic Name

English

Xantinol nicotinate [WHO-DD]

Common Name

English

(±)-7-(2-HYDROXY-3-((2-HYDROXYETHYL)METHYLAMINO)PROPYL)THEOPHYLLINE, COMPOUND WITH NICOTINIC ACID (1:1)

Systematic Name

English

XANTINOL NICOTINATE [MART.]

Common Name

English

3-PYRIDINECARBOXYLIC ACID COMPD. WITH 3,7-DIHYDRO-7-(2-HYDROXY-3-((2-HYDROXYETHYL)METHYLAMINO)PROPYL)-1,3-DIMETHYL-1H-PURINE-2,6-DIONE (1:1)

Systematic Name

English

NSC-113217

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C29707